Virtual Network's Login.
SESSION I – GENETIC AND CELLULAR PATHOGENESIS OF MPNs
Splicing factor-mutant myeloid neoplasms – Mario Cazzola
Causes of myeloproliferative disorders– Mary-Frances McMullin
Novel oncogenic mechanisms in myeloproliferative neoplasms: the mutated chaperon calreticulin embracing cytokine receptors – Stefan N. Constantinescu
The genomic basis of acute lymphoblastic leukaemia– Charles G. Mullighan
The genomics of MPNs– Peter Campbell
SESSION II – NOVEL MPN THERAPEUTICS
Epigenetic alterations and therapeutic targeting in MPN – Ross L. Levine
Role of megakaryocytes in the MPNs– John D. Crispino
Molecular insights into regulation of JAK2 in MPN– Olli Silvennoinen
Using molecular information to inform patient management – Alessandro M. Vannucchi
Targeting JAK2 – Have we arrived?– Thomas Radimerski
SESSION III – MECHANISMS OF MYELOID TRANSFORMATION AND PROGRESSION
Cellular and molecular response to interferon therapy in PV and ET – Josef T. Prchal
Functional and molecular dissection of molecular drivers in MPN – Ann Mullally
MPN pathogenesis and JAK/STAT signalling – Tony R. Green
Bone marrow niches for HSCs in MPN – Simón Méndez-Ferrer
What is new about the pathogenesis of thrombosis in MPN in 2016? – Chloé James
SESSION IV – MURINE MODELING OF MPN
Stem cell origin of myeloproliferative neoplasms – Radek Skoda
Modeling predisposition to familial MPN– Isabelle Plo
Preclinical analysis of linsitinib for the treatment of polycythemia vera – Heike L. Pahl
Modeling the calreticulin disease in mice – William Vainchenker
SESSION V – TARGETING THE MPN STEM CELL
RNA rewriting, recoding and rewiring in myeloproliferative neoplasms stem cells – Catriona Jamieson
Optimize transplant results in myelofibrosis – Nicolaus Kröger
Using single cell biology to identify stem cell fate regulators in haematological malignancies– David Kent
The effects of specialized microenvironments on haematopoiesis in myelofibrosis– Ronald Hoffman
SESSION VI – RECENT ADVANCES IN MANAGEMENT
Natural history and risk stratification of prefibrotic myelofibrosis – Giovanni Barosi
An update of interferon trials in MPN – Jean-Jacques Kiladjian
SESSION VII – RECENT ADVANCES IN MANAGEMENT 2
Rethinking the treatment recommendations in low-risk PV – Tiziano Barbui
Next generation MPN management– Ruben A. Mesa
Promises and pitfalls of JAK inhibitor therapy – Claire Harrison
